202 related articles for article (PubMed ID: 29246775)
1. Coronary ectasia in amyloid cardiomyopathy and neuropathy due to the transthyretin mutation c.323A>G.
Finsterer J; Stöllberger C; Rauschka H; Gatterer E
Heart Lung; 2018; 47(2):127-129. PubMed ID: 29246775
[TBL] [Abstract][Full Text] [Related]
2. Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis.
Salvi F; Volpe R; Pastorelli F; Bianchi A; Vella A; Rapezzi C; Mascalchi M
J Stroke Cerebrovasc Dis; 2018 Sep; 27(9):e212-e214. PubMed ID: 29779881
[TBL] [Abstract][Full Text] [Related]
3. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.
Maurer MS; Grogan DR; Judge DP; Mundayat R; Packman J; Lombardo I; Quyyumi AA; Aarts J; Falk RH
Circ Heart Fail; 2015 May; 8(3):519-26. PubMed ID: 25872787
[TBL] [Abstract][Full Text] [Related]
4. Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report.
Yamamoto H; Hashimoto T; Kawamura S; Hiroe M; Yamashita T; Ando Y; Yokochi T
J Med Case Rep; 2018 Dec; 12(1):370. PubMed ID: 30553273
[TBL] [Abstract][Full Text] [Related]
5. Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: A phase III, open-label study.
Ando Y; Sekijima Y; Obayashi K; Yamashita T; Ueda M; Misumi Y; Morita H; Machii K; Ohta M; Takata A; Ikeda S
J Neurol Sci; 2016 Mar; 362():266-71. PubMed ID: 26944161
[TBL] [Abstract][Full Text] [Related]
6. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
Sekijima Y
J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
[TBL] [Abstract][Full Text] [Related]
7. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
Paton DM
Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
[TBL] [Abstract][Full Text] [Related]
8. Hereditary transthyretin-related amyloidosis.
Finsterer J; Iglseder S; Wanschitz J; Topakian R; Löscher WN; Grisold W
Acta Neurol Scand; 2019 Feb; 139(2):92-105. PubMed ID: 30295933
[TBL] [Abstract][Full Text] [Related]
9. Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area.
Cortese A; Vita G; Luigetti M; Russo M; Bisogni G; Sabatelli M; Manganelli F; Santoro L; Cavallaro T; Fabrizi GM; Schenone A; Grandis M; Gemelli C; Mauro A; Pradotto LG; Gentile L; Stancanelli C; Lozza A; Perlini S; Piscosquito G; Calabrese D; Mazzeo A; Obici L; Pareyson D
J Neurol; 2016 May; 263(5):916-924. PubMed ID: 26984605
[TBL] [Abstract][Full Text] [Related]
10. Effects of liver transplantation and tafamidis in hereditary transthyretin amyloidosis caused by transthyretin Leu55Pro mutation: a case report.
Kon T; Misumi Y; Nishijima H; Honda M; Suzuki C; Baba M; Inomata Y; Obayashi K; Ando Y; Tomiyama M
Amyloid; 2015; 22(3):203-4. PubMed ID: 26123280
[No Abstract] [Full Text] [Related]
11. Tafamidis for transthyretin amyloidosis.
de Lartigue J
Drugs Today (Barc); 2012 May; 48(5):331-7. PubMed ID: 22645721
[TBL] [Abstract][Full Text] [Related]
12. Amyloid Polyneuropathy and Myocardial Amyloidosis 10 Years after Domino Liver Transplantation from a Patient with a Transthyretin Ser50Arg Mutation.
Matsushima M; Yabe I; Tsuda M; Sakakibara M; Shimamura T; Sasaki H
Intern Med; 2017 Dec; 56(23):3231-3235. PubMed ID: 28943540
[TBL] [Abstract][Full Text] [Related]
13. Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study.
Planté-Bordeneuve V; Gorram F; Salhi H; Nordine T; Ayache SS; Le Corvoisier P; Azoulay D; Feray C; Damy T; Lefaucheur JP
J Neurol; 2017 Feb; 264(2):268-276. PubMed ID: 27878441
[TBL] [Abstract][Full Text] [Related]
14. A Comprehensive Review on Chemistry and Biology of Tafamidis in Transthyretin Amyloidosis.
Patil MB; Ghode P; Joshi P
Mini Rev Med Chem; 2024; 24(6):571-587. PubMed ID: 37828667
[TBL] [Abstract][Full Text] [Related]
15. Tafamidis (Vyndaqel): a light for FAP patients.
Nencetti S; Rossello A; Orlandini E
ChemMedChem; 2013 Oct; 8(10):1617-9. PubMed ID: 24000164
[TBL] [Abstract][Full Text] [Related]
16. Clinical and pathological findings in familial amyloid polyneuropathy caused by a transthyretin E61K mutation.
Murakami T; Nishimura H; Nagai T; Hemmi S; Kutoku Y; Ohsawa Y; Sunada Y
J Neurol Sci; 2017 Oct; 381():55-58. PubMed ID: 28991715
[TBL] [Abstract][Full Text] [Related]
17. Oculoleptomeningeal Amyloidosis Secondary to the Rare Transthyretin c.381T>G (p.Ile127Met) Mutation.
Mathieu F; Morgan E; So J; Munoz DG; Mason W; Kongkham P
World Neurosurg; 2018 Mar; 111():190-193. PubMed ID: 29277593
[TBL] [Abstract][Full Text] [Related]
18. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.
Coelho T; Maia LF; Martins da Silva A; Waddington Cruz M; Planté-Bordeneuve V; Lozeron P; Suhr OB; Campistol JM; Conceição IM; Schmidt HH; Trigo P; Kelly JW; Labaudinière R; Chan J; Packman J; Wilson A; Grogan DR
Neurology; 2012 Aug; 79(8):785-92. PubMed ID: 22843282
[TBL] [Abstract][Full Text] [Related]
19. Transthyretin familial amyloid polyneuropathy.
Planté-Bordeneuve V; Kerschen P
Handb Clin Neurol; 2013; 115():643-58. PubMed ID: 23931808
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of familial amyloid polyneuropathy].
Adams D; Samuel D; Slama M
Presse Med; 2012 Sep; 41(9 Pt 1):793-806. PubMed ID: 22341949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
